Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,761
archived clinical trials in
Osteoporosis

TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/10/2015
Phillip J. Mease
mi
from
Seattle, WA
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/10/2015
Phillip J. Mease
mi
from
Seattle, WA
Click here to add this to my saved trials
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/10/2015
'Osteoporosis Research Group
mi
from
Seattle, WA
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/10/2015
'Osteoporosis Research Group
mi
from
Seattle, WA
Click here to add this to my saved trials
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/10/2015
'University of Wisconsin Medical Foundation
mi
from
Madison, WI
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/10/2015
'University of Wisconsin Medical Foundation
mi
from
Madison, WI
Click here to add this to my saved trials
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/10/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/10/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/10/2015
'IDIM
mi
from
Buenos Aires,
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/10/2015
'IDIM
mi
from
Buenos Aires,
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Pivotal Research
mi
from
Peoria, AZ
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Pivotal Research
mi
from
Peoria, AZ
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Loma Linda Osteoporosis Research Clinic
mi
from
Loma Linda, CA
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Loma Linda Osteoporosis Research Clinic
mi
from
Loma Linda, CA
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Steven Harris
mi
from
Mill Valley, CA
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Steven Harris
mi
from
Mill Valley, CA
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
John Wayne Cancer Institute
mi
from
Santa Monica, CA
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
John Wayne Cancer Institute
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Paul Miller
mi
from
Lakewood, CO
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Paul Miller
mi
from
Lakewood, CO
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Longmont Medical Research Network
mi
from
Longmont, CO
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Longmont Medical Research Network
mi
from
Longmont, CO
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Radiant Research, Stuart
mi
from
Stuart, FL
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Radiant Research, Stuart
mi
from
Stuart, FL
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Maine Center for Osteoporosis Research and Education of St. Joseph's Hospital
mi
from
Bangor, ME
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Maine Center for Osteoporosis Research and Education of St. Joseph's Hospital
mi
from
Bangor, ME
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
'Bethesda Health Research Center
mi
from
Bethesda, MD
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
'Bethesda Health Research Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Helen Hayes Hospital
mi
from
West Haverstraw, NY
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Helen Hayes Hospital
mi
from
West Haverstraw, NY
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Oregon Osteoporosis Center
mi
from
Portland, OR
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Oregon Osteoporosis Center
mi
from
Portland, OR
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Simona Scumpia
mi
from
Austin, TX
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Simona Scumpia
mi
from
Austin, TX
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Radiant Research Dallas
mi
from
Dallas, TX
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Radiant Research Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
'Diabetes & Glandular Disease Research Associates, P.A.
mi
from
San Antonio, TX
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
'Diabetes & Glandular Disease Research Associates, P.A.
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Northwest Lipid Research Center
mi
from
Seattle, WA
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Northwest Lipid Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Heritage Medical Research Clinic
mi
from
Calgary,
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Heritage Medical Research Clinic
mi
from
Calgary,
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
Osteoporosis Medical Center
mi
from
Beverly Hills, CA
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
Osteoporosis Medical Center
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
University of Chicago
mi
from
Chicago, IL
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
Michigan Bone and Mineral Clinic, PC
mi
from
Detroit, MI
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
Michigan Bone and Mineral Clinic, PC
mi
from
Detroit, MI
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
'Odyssey Research Services
mi
from
Bismarck, ND
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
'Odyssey Research Services
mi
from
Bismarck, ND
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
Michael J. Lillestol
mi
from
Fargo, ND
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
Michael J. Lillestol
mi
from
Fargo, ND
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
'Odyssey Research Services
mi
from
Minot, ND
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
'Odyssey Research Services
mi
from
Minot, ND
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
'Rapid City Medical Center
mi
from
Rapid City, SD
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
'Rapid City Medical Center
mi
from
Rapid City, SD
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
Brown Clinic
mi
from
Watertown, SD
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
Brown Clinic
mi
from
Watertown, SD
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
'Fletcher Allan Health Center, UHC Campus 1
mi
from
Burlington, VT
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
'Fletcher Allan Health Center, UHC Campus 1
mi
from
Burlington, VT
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
'IDIM
mi
from
Buenos Aires,
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
'IDIM
mi
from
Buenos Aires,
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
'Radiant Research - Phoenix North
mi
from
Phoenix, AZ
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
'Radiant Research - Phoenix North
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
Osteoporosis Medical Center
mi
from
Beverly Hills, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
Osteoporosis Medical Center
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
East Bay Clinical Trial Center
mi
from
Concord, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
East Bay Clinical Trial Center
mi
from
Concord, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
'Loma Linda Osteoporosis Research Center
mi
from
Loma Linda, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
'Loma Linda Osteoporosis Research Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
Foundation for Osteoporosis Research
mi
from
Oakland, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
Foundation for Osteoporosis Research
mi
from
Oakland, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
Desert Medical Advances
mi
from
Palm Desert, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
Desert Medical Advances
mi
from
Palm Desert, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
'Boling Clinical Trials
mi
from
Rancho Cucamonga, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
'Boling Clinical Trials
mi
from
Rancho Cucamonga, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
'S.D. Arthritis & Osteoporosis Medical Clinic
mi
from
san Diego, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
'S.D. Arthritis & Osteoporosis Medical Clinic
mi
from
san Diego, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
'Radiant Research - San Diego
mi
from
San Diego, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
'Radiant Research - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
San Francisco General Hospital
mi
from
San Francisco, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
San Francisco General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
Longmont Medical Research Network
mi
from
Longmont, CO
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
Longmont Medical Research Network
mi
from
Longmont, CO
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
'Northeast Clinical Research, LLC
mi
from
Hamden, CT
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
'Northeast Clinical Research, LLC
mi
from
Hamden, CT
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
RASF Clinical Research Center
mi
from
Boca Raton, FL
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
RASF Clinical Research Center
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
The Center for Diabetes and Endocrine Care
mi
from
Hollywood, FL
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
The Center for Diabetes and Endocrine Care
mi
from
Hollywood, FL
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
'Florida Wellcare Alliance
mi
from
Inverness, FL
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
'Florida Wellcare Alliance
mi
from
Inverness, FL
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
'Renstar Medical Group
mi
from
Ocala, FL
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
'Renstar Medical Group
mi
from
Ocala, FL
Click here to add this to my saved trials